Rising Cases of Rheumatic Disease Can Fibromyalgia Treatment Market

Pune, India, February,2019/MRFR Press Release/- Market Research Future has published a half-cooked research report on the Global Fibromyalgia Treatments Market.

Overview:

The global fibromyalgia treatment market, as per the reports of Market Research Future (MRFR), is all set to witness substantial gain in CAGR during the forecast period (2017-2023). Its market valuation can expect an upliftment as a square impact of the rise. Fibromyalgia, also known as fibromyalgia syndrome (FMS), is a condition where the body feels pain, and it persists for a long time. As its side-effects, people start feeling increased sensitivity to pain, fatigue, muscle stiffness, lack of sleep, headache, poor digestive condition, lack of concentration and weak memory. Fibromyalgia gets triggered by abnormalities in the brain and poor condition of the central nervous system. Heredity has some part to play as well in triggering such a disease. Also, emotionally stressful events can provoke such disease into attacking the body. It can be treated via medication, therapies, and significant lifestyle changes. MRFR in their recently published report on the fibromyalgia treatment market included segments and drivers that can provide greater insight regarding the upcoming market.

Traumatic stress and road accidents can be among the major factors that can promote the fibromyalgia treatment market in the coming years. The psychiatric disorder can also trigger such cases. In a journal published by the Pain Research and Management Journal, in 2014, researchers said that physical trauma often is followed by fibromyalgia. Rheumatic diseases play a pivotal role as well. These diseases affect joints more, and as its direct impact, muscles can show signs of fibromyalgia. However, Chinese treatments are fast becoming popular which can inspire the fibromyalgia treatment market in exploring previously uncharted territories. 

Segmentation:

MRFR report on the fibromyalgia treatment market is segmented by treatment, diagnosis, and end-user, for a better understanding of the upcoming years.

Based on the treatment, the fibromyalgia treatment market is segmented into symptomatic treatment and targeted treatment.

Based on the diagnosis, the fibromyalgia treatment market includes laboratory evaluation and the presence of central sensitization.

Based on the end-user, the fibromyalgia treatment market comprises hospitals, clinics, diagnostic centers, and others.Browse Complete Report @ https://www.marketresearchfuture.com/reports/fibromyalgia-treatments-market-1879

Regional Analysis

MRFR, regionally, analyzes the fibromyalgia treatment market by including the Americas, Europe, Asia Pacific (APAC), and Middle East & Africa (MEA).

The Americas has dominance over the fibromyalgia treatment market as the rising cases of rheumatic diseases are getting registered in numbers. The regional market also gains much from the growing awareness among the people who are now looking for group therapies and other modes of treatment. As per the reports of the Centers for Disease Control and Prevention (CDC) by 2040, around 78 million adults are deemed to register cases regarding arthritis in the United States which can show how much the market can expand.

Europe’s prominence in the market depends mostly on government initiatives and research & laboratories that are continuously trying to develop new products. However, it is the APAC market that can astound many by projecting a huge market valuation for itself. The APAC is benefitting much from the huge patient pool and increasing healthcare expenditure. For instance, China’s healthcare sector leaps each year by almost 11.6%, which is definitely a good sign for the market in the upcoming days.

Competitive Landscape:

Prominent players engaged in the fibromyalgia treatment market, as are Pfizer, Johnson & Johnson Services, Inc., GlaxoSmithKline, Astellas Pharma, AstraZeneca, F. Hoffmann-La Roche AG, SANOFI, Eli Lilly and Company, Jazz Pharmaceuticals, Bayer AG, ALLERGAN, AbbVie, Boehringer Ingelheim, Cephalon, Inc., Vertical Pharmaceuticals, Sunovion Pharms Inc, ABBOTT, NOVARTIS, and others.

In 2018, researchers at the Optics and Photonics Research Center described that laser light and therapeutic ultrasound in low intensity, when applied on the palm, can reduce the pain of fibromyalgia by 75%.

FDA approved the commercialization of IMC-1, which is a combination of famciclovir, an antiviral agent, and celecoxib, an anti-inflammatory. The medicine showed great signs in improving fibromyalgia.